At Takeda Oncology, we endeavor to deliver novel medicines to patients with cancer worldwide through
our commitment to science, breakthrough innovation and passion for improving the lives of patients.
This singular focus drives our aspirations to discover, develop and deliver breakthrough oncology therapies.
By concentrating the power of leading scientific minds and the vast resources of a global pharmaceutical
company, we are finding innovative ways to improve the treatment of cancer.
We’ve built a portfolio of paradigm-changing therapies and a leading oncology pipeline. Though we’ve made great
strides in our fight against cancer, we are determined to do more – to work harder and to reach higher. We continue
to seek our aspirations with the same passion, agility and entrepreneurial spirit that has sustained our patient-centric
culture and has made us the leaders in oncology that we are today.
We know that our mission is not a quick or simple one, but we are up for the task: we aspire to cure cancer.
To learn more, visit us at takedaoncology.com.
@TakedaOncology
©2016 Millennium Pharmaceuticals, Inc. All rights reserved.
SCIENTIFIC
PROGRAMME
SESSION I
SMOLDERING
MYELOMA
SESSION II
DIAGNOSIS OF
MULTIPLE MYELOMA
SESSION III
FRONTLINE THERAPY
IN PATIENTS NOT
ELIGIBLE FOR
AUTOLOGOUS
STEM CELL
TRANSPLANTATION
SESSION IV
FRONTLINE THERAPY
IN PATIENTS
ELIGIBLE FOR
AUTOLOGOUS
STEM CELL
TRANSPLANTATION
SESSION V
MRD AND THE
MICROENVIRONMENT
SESSION VI
RELAPSED MULTIPLE
MYELOMA
SESSION VII
THE FUTURE :
RECENT CLINICAL
TRIALS IN RELAPSE
SESSION VIII
DATA MANAGEMENT
ISSUES
SESSION IX
PLASMA CELL
DISORDERS
SELECTED
ABSTRACTS FOR AN
ORAL PRESENTATION
ABSTRACTS
SELECTED AS
POSTERS
DISCLOSURES